2026 TeoTwawKi ... 2032 Darkest Interregnum Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : 2026 TeoTwawKi ... 2032 Darkest Interregnum

GLD 389.05

+0.4%

Dec 10 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: sense who wrote (154651)	3/18/2020 4:57:16 AM
From: TobagoJack	4 Recommendations Recommended By Dr. Voodoo marcher pak73 Secret_Agent_Man Read Replies (3) of 218381

some possible good news just in in tray, lock-limit-up, also trade in USA would not want to be too short NY open, but a good moment to start collect some lemons to squeeze before end of trading session finance.yahoo.com On 18 Mar 2020, at 10:14 AM, S wrote: Dear All, Believe it or not ... China says Japan-developed flu drug works against coronavirus An influenza medicine developed by a Fujifilm Holdings group member is effective against the novel coronavirus, the Chinese government said Tuesday. The government plans to officially recommend the drug's use for treatment. Fujifilm Toyoma Chemical developed favipiravir, sold under the brand Avigan. "It has a high degree of safety and is clearly effective in treatment," said Zhang Xinmin, director of the science ministry's China National Center for Biotechnology Development, in a news conference. Fujifilm Toyoma Chemical developed the drug in 2014, and it has been provided to patients in Japan as treatment for the novel cornonavirus since February. Zhejiang Hisun Pharmaceutical signed a patent-licensing agreement for favipiravir with Fujifilm in 2016. The drugmaker received clearance to produce the drug from Chinese authorities in February and can ramp up output of a generic version. The clinical trial was conducted at hospitals in Wuhan and Shenzhen, with 200 patients participating. Test results for those receiving the drug turned negative in a shorter period, and their pneumonia symptoms improved at a higher rate. finance.yahoo.com finance.yahoo.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next